Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2007
Price :
$35
*
At a glance
- Drugs Iodine (Primary)
- Indications Breast pain
- Focus Therapeutic Use
- Sponsors Symbollon Pharmaceuticals
- 26 Jul 2007 The expected completion date for this trial is now 1 Mar 2008.
- 15 Jun 2007 Status change from recruiting to in progress.
- 02 Feb 2007 New trial cetnres added.